Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology
Open Access
- 28 December 2020
- journal article
- review article
- Published by MDPI AG in Nanomaterials
- Vol. 11 (1), 59
- https://doi.org/10.3390/nano11010059
Abstract
Alzheimer’s disease (AD), a progressively fatal neurodegenerative disorder, is the most prominent form of dementia found today. Patients suffering from Alzheimer’s begin to show the signs and symptoms, like decline in memory and cognition, long after the cellular damage has been initiated in their brain. There are several hypothesis for the neurodegeneration process; however, the lack of availability of in vivo models makes the recapitulation of AD in humans impossible. Moreover, the drugs currently available in the market serve to alleviate the symptoms and there is no cure for the disease. There have been two major hurdles in the process of finding the same—the inefficiency in cracking the complexity of the disease pathogenesis and the inefficiency in delivery of drugs targeted for AD. This review discusses the different drugs that have been designed over the recent years and the drug delivery options in the field of nanotechnology that have been found most feasible in surpassing the blood–brain barrier (BBB) and reaching the brain.Funding Information
- National Research Foundation of Korea ((No. 2018R1D1A1B07040673, No. 2014R1A5A2010008))
This publication has 161 references indexed in Scilit:
- Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokineticsNanomedicine: Nanotechnology, Biology and Medicine, 2011
- Presenilins and -Secretase: Structure, Function, and Role in Alzheimer DiseaseCold Spring Harbor Perspectives in Medicine, 2011
- Crystal structures of the extracellular domain of LRP6 and its complex with DKK1Nature Structural & Molecular Biology, 2011
- An Overview of APP Processing Enzymes and ProductsNeuroMolecular Medicine, 2009
- Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domainProceedings of the National Academy of Sciences of the United States of America, 2009
- Wnt-mediated activation of NeuroD1 and retro-elements during adult neurogenesisNature Neuroscience, 2009
- Wnt/β-Catenin Signaling: Components, Mechanisms, and DiseasesDevelopmental Cell, 2009
- New Therapeutic Targets in the Neurovascular Pathway in Alzheimer's DiseaseNeurotherapeutics, 2008
- The GSK3 hypothesis of Alzheimer’s diseaseJournal of Neurochemistry, 2007
- Regulation of phosphorylation of tau by cyclin‐dependent kinase 5 and glycogen synthase kinase‐3 at substrate levelFEBS Letters, 2006